Showing 4641-4650 of 5623 results for "".
- Staar Surgical Begins Commercialization of EVO Viva Presbyopia Correcting Lenshttps://modernod.com/news/staar-surgical-begins-commercialization-of-evo-viva-presbyopia-correcting-lens/2478495/Staar Surgical announced the initial commercialization of its EVO Viva presbyopia correcting lens including the first patient implant. “The first patient received his EVO Viva lenses on October 23 in Belgium from Dr. Erik Mertens, and we are delighted to hear from Dr. Mertens that the pati
- What a Republican Senate Will Mean for the Health Care Industryhttps://modernod.com/news/what-a-republican-senate-will-mean-for-the-health-care-industry/2478493/Republicans appear likely to hold on slightly to their Senate majority after Tuesday’s elections, which could have a major impact on what healthcare legislation gets through Congress next year, according to a FierceHealthcare
- PolyActiva Completes Initial Clinical Trial With Latanoprost FA SR Ocular Implant for 6-Month Glaucoma Treatmenthttps://modernod.com/news/polyactiva-completes-initial-clinical-trial-with-latanoprost-fa-sr-ocular-implant-for-6-month-glaucoma-treatment/2478494/PolyActiva announced it has successfully completed its phase I clinical study for its lead candidate, the Latanoprost FA SR Ocular Implant. The device was well tolerated in all 8 patients with no significant safety findings. The study also showed that the implant persists for the entire 6-
- Lineage Cell Therapeutics to Host Expert Call Following OpRegen Data Update at 2020 AAO Meetinghttps://modernod.com/news/lineage-cell-therapeutics-to-host-expert-call-following-opregen-data-update-at-2020-aao-meeting/2478483/Lineage Cell Therapeutics will be hosting a call to discuss updated interim results from the phase 1/2a study of its lead product candidate, OpRegen, with one of the study’s principal investigators. OpRegen is a retinal pigment epithelium (RPE) cell transplant therapy currently in development for
- Internal Documents Reveal COVID-19 Hospitalization Data The Government Keeps Hiddenhttps://modernod.com/news/internal-documents-reveal-covid-19-hospitalization-data-the-government-keeps-hidden/2478485/As coronavirus cases rise swiftly around the country, surpassing both the spring and summer surges, health officials brace for a coming wave of hospitalizations and deaths. Knowing which hospitals in which communities are reaching capacity could be key to an effective response to the growing cris
- Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy for Dry AMD Via Orbit SDShttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-for-dry-amd-via-orbit-subretinal-delivery-system/2478480/Gyroscope Therapeutics announced that the first surgery using its proprietary Orbit Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been condu
- Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseaseshttps://modernod.com/news/ocumension-therapeutics-strengthens-pipeline-for-posterior-segment-eye-diseases/2478482/Ocumension Therapeutics announced that the company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology, a wholly-owned subsidiary of Luye Pharma Group, to jointly develop OT-702 (LY09004), a biosimilar to Eylea (aflibercept). Ocumension has
- Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindnesshttps://modernod.com/news/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-for-treating-blindness/2478474/Novartis announced that it has acquired Vedere Bio, adding a new platform for AAV-based delivery of gene therapies and an optogenetics program. The acquisition will enable Novartis to advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.
- Santen and Aerie Conclude Exclusive License Agreement for Rhopressa and Rocklatan in Japan and Several Other Asian Countrieshttps://modernod.com/news/santen-and-aerie-conclude-exclusive-license-agreement-for-rhopressa-and-rocklatan-in-japan-and-several-other-asian-countries/2478469/Santen Pharmaceutical and Aerie Pharmaceuticals announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa and Rocklatan in Japan, along with rights for several other Asian countries. Rhopressa (netarsudil ophthalmic solution) 0
- iVeena Announces Positive Topline Results of IVMED-80 Eye Drops for Keratoconushttps://modernod.com/news/iveena-announces-positive-topline-results-of-ivmed-80-eye-drops-for-keratoconus/2478466/iVeena has announced topline results of its recently completed phase 1/2a clinical trial, “A Randomized, Double-Masked, Trial of IVMED-80 Eyedrops for Treatment of Keratoconus.” The study objective was to determine whether a 6- or 16-week course of twice-daily IVMED-80 eyedrops (vs. placebo) coul